SNV

Synovus Financial Corp. releases 2023 Annual Report

Retrieved on: 
Thursday, April 11, 2024
Payments, Finance, Banking, Data Management, Accounting, Professional Services, Technology, Fintech, Investment, Annual report, Synovus, SNV

Synovus Financial Corp. (NYSE: SNV) has released its 2023 Annual Report, which highlights the company’s progress toward its strategic priorities, including key initiatives and investments that bring its purpose to life for clients, team members, communities and all stakeholders.

Key Points: 
  • Synovus Financial Corp. (NYSE: SNV) has released its 2023 Annual Report, which highlights the company’s progress toward its strategic priorities, including key initiatives and investments that bring its purpose to life for clients, team members, communities and all stakeholders.
  • “Focused on the continued execution of our strategic priorities throughout 2023, we simultaneously navigated unforeseen challenges, adapted swiftly and upheld our commitment to clients – proactive advice, customized solutions and unrelenting support while fostering growth,” said Synovus Chairman, CEO and President Kevin Blair.
  • Read the Synovus 2023 Annual Report to learn more about how the company delivered on its purpose and its emphasis on growing the bank in 2024 and beyond.
  • Synovus Financial Corp. is a financial services company based in Columbus, Georgia, with approximately $60 billion in assets.

Hartwig and Ultima Genomics Collaborate to Reduce Costs for Whole Genome Cancer Profiling, Minimal Residual Disease Testing and Generating Genetic Data at Scale

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Medical Devices, Health, Genetics, Oncology, Database, Genetic testing, Disease, Patient, NGS, Research, Cancer, Ultima, Architecture, MRD, Medical foundation, Hartwig, Blood, SNV, Medical imaging

This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.

Key Points: 
  • This collaboration aims to reduce test costs and make complete genome-based cancer diagnostics accessible for more patients to have better informed cancer treatment.
  • In parallel, platform strengths will be explored for minimal residual disease detection in blood of cancer patients with a one-size-fits-all solution that builds on pre-existing complete tumor profile information.
  • “Collaborating with Hartwig to deploy our technology toward whole genome cancer profiling, MRD testing and generating genomic information at scale is an exciting milestone,” said Gilad Almogy, CEO of Ultima Genomics.
  • Furthermore, lower costs can enable Hartwig to affordably create genetic datasets at national population scale to improve cancer research and ultimately outcomes for future patients.

Takara Bio transforms single-cell landscape with new large-scale NGS profiling system for oncology biomarker discovery

Retrieved on: 
Tuesday, April 2, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Cell, NGS, Biomarker, RNA, ABRF, Messenger, Head, AACR, Chemistry, Neoplasm, Booth, RNA-Seq, WGA, SNV, Annual general meeting, CNV, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Shasta™ Single-Cell System, an automated, high-throughput NGS solution with well-validated chemistries and intuitive bioinformatics tools that enables novel biomarker discovery for oncology research.
  • Existing whole-genome amplification (WGA) technologies currently process 96–384 single cells per plate; the Shasta system increases WGA throughput to 1,500 cells per run.
  • In March, Takara Bio USA delivered instruments and NGS kits to early-access users, who have started producing results with the system.
  • We have two other projects in the lab where we want to do a full set of profiling of our entire model system.

BioSkryb Genomics to Present Novel Research on Tumor Heterogeneity at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Single-cell analysis, Disease, Transcriptome, Malignancy, Neoplasm, DNA, Genome, Workflow, AACR, Doctor of Philosophy, Phenotype, Genomics, SNV, Ageing, CNV, Mobile phone

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.
  • “Tumor heterogeneity is a key challenge for researchers in the cancer research field.
  • As tumors evolve, subclones emerge with mutations that convey adaptive phenotypes, including resistance to therapies,” said Suresh Pisharody, CEO of BioSkryb.
  • “Our next generation single-cell technology gives scientists the tools to better understand the way tumors evolve with a comprehensive, scalable, and streamlined workflow.

Synovus to announce first quarter 2024 earnings results

Retrieved on: 
Monday, March 18, 2024
Banking, Asset Management, Professional Services, Finance, SNV, Synovus, Table

Synovus Financial Corp. (NYSE: SNV) will announce first quarter 2024 earnings results after the market closes on Wednesday, April 17, 2024, and host a conference call at 8:30 a.m.

Key Points: 
  • Synovus Financial Corp. (NYSE: SNV) will announce first quarter 2024 earnings results after the market closes on Wednesday, April 17, 2024, and host a conference call at 8:30 a.m.
  • A live audio webcast and slides will be available with the press release and tables at http://investor.synovus.com/event .
  • Synovus Financial Corp. is a financial services company based in Columbus, Georgia, with approximately $60 billion in assets.
  • Synovus is a Great Place to Work-Certified Company and is on the web at synovus.com , and on X , formerly known as Twitter, Facebook , LinkedIn and Instagram .

Synovus Announces Quarterly Dividends

Retrieved on: 
Monday, March 4, 2024
Banking, Professional Services, Finance, SNV, Synovus

The board of directors of Synovus Financial Corp. (NYSE: SNV) has declared the following quarterly dividends:

Key Points: 
  • The board of directors of Synovus Financial Corp. (NYSE: SNV) has declared the following quarterly dividends:
    $0.38 per share on the company’s common stock, payable on April 1, 2024, to shareholders of record as of March 21, 2024.
  • Synovus Financial Corp. is a financial services company based in Columbus, Georgia, with approximately $60 billion in assets.
  • Synovus has branches in Georgia, Alabama, South Carolina, Florida and Tennessee.
  • Synovus is a Great Place to Work-Certified Company and is on the web at synovus.com and on X , formerly known as Twitter, Facebook , LinkedIn and Instagram .

Ultima Announces UG 100™ and Reveals Disruptive Cost and Accuracy Profile to Enable the Era of the $100 Genome and Beyond

Retrieved on: 
Tuesday, February 6, 2024
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Genomics, Robotics, Ultima, Machine learning, GIAB, TB, Automation, Q60, Biology, Algorithm, Genome, SNV

The UG 100TM system also leverages recent advancements in machine learning to improve base calling and variant calling algorithms for improved accuracy and performance.

Key Points: 
  • The UG 100TM system also leverages recent advancements in machine learning to improve base calling and variant calling algorithms for improved accuracy and performance.
  • This scalable configuration enables the $100 genome at an industry-leading price of $1.00 per Gb or $0.30 per million reads.
  • Today, the Company is also introducing ppmSeqTM, a disruptive new mode for extreme raw read accuracy in calling single nucleotide variants (SNVs).
  • With the launch of the UG 100TM system, Ultima looks to enable the next wave of biology powered by low-cost sequencing data generation.

Takara Bio’s First-to-Market Large-Scale Single-Cell NGS Profiling Technologies Poised to Revolutionize Biomarker Discovery

Retrieved on: 
Monday, February 5, 2024
Oncology, Medical Supplies, Health, Genetics, Research, Science, Biotechnology, Neoplasm, Cell, B cell, Biomarker, CNV, RNA-Seq, NGS, RNA, SNV, Antibiotics

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced plans to launch two critical solutions for oncology research.
  • The Shasta™ Total RNA-Seq Kit will detect splicing isoforms, gene fusions, and non-polyadenylated RNAs through full-length transcriptome profiling of up to 100,000 single cells per run.
  • “Our new kits will break the limits of current methods to enable true biological discovery,” said Carol Lou, President & CEO of Takara Bio USA.
  • With the new Shasta™ technologies, Takara Bio will introduce first-to-market high-scale solutions that can pick up important genetic events other technologies miss.

Synovus to participate at BofA Securities Financial Services Conference

Retrieved on: 
Wednesday, January 31, 2024
Banking, Asset Management, Professional Services, Finance, Synovus, SNV, Conference

Synovus Financial Corp. (NYSE: SNV) Chairman, CEO and President Kevin Blair will participate in a fireside chat at the 32nd annual BofA Securities Financial Services Conference at 1 Hotel South Beach in Miami Beach, Florida, on Feb. 21, 2024, at 3:20 p.m.

Key Points: 
  • Synovus Financial Corp. (NYSE: SNV) Chairman, CEO and President Kevin Blair will participate in a fireside chat at the 32nd annual BofA Securities Financial Services Conference at 1 Hotel South Beach in Miami Beach, Florida, on Feb. 21, 2024, at 3:20 p.m.
  • Synovus Financial Corp. is a financial services company based in Columbus, Georgia, with approximately $60 billion in assets.
  • Synovus provides commercial and consumer banking and a full suite of specialized products and services, including private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets and international banking.
  • Synovus is a Great Place to Work-Certified Company and is on the web at synovus.com and on X , formerly known as Twitter, Facebook , LinkedIn and Instagram .

Ultima Genomics Announces End of Early Access and Upcoming Launch of UG 100™

Retrieved on: 
Tuesday, January 30, 2024
Biotechnology, Pharmaceutical, Medical Supplies, Oncology, Health, Medical Devices, Health Technology, Genetics, Partnership, Whole genome sequencing, Genomics, Liquid biopsy, Workflow, Gold, Research, DNA, Access, Science, Environment, Patient, Exact sciences, Diagnosis, CLIA, Broad Institute, Laboratory, Chemistry, Harvard University, Drug discovery, Automation, Weill Cornell Medicine, Disease, Biophysics, Silicon, Biology, MIT, Physiology, Doctor of Philosophy, Medicine, Cancer, Genome, Early access, SNV

The UG 100™ is an ultra-high throughput system purposefully built for high-volume applications.

Key Points: 
  • The UG 100™ is an ultra-high throughput system purposefully built for high-volume applications.
  • “After much anticipation, we are excited to publicly announce the full commercial availability of the $100 genome at the upcoming AGBT conference in February,” said Gilad Almogy, Founder and CEO of Ultima.
  • We are excited to be an early adopter of Ultima’s technology and the first to have the instrument installed in the Asia-Pacific region.
  • Ultima will be introducing the UG 100™ and will be providing additional information about its ppmSeq™ technology on February 6th at the AGBT conference as part of its Gold Sponsorship plenary presentation.